Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)

• Published in: Advances in therapy 2020-04, Vol.37 (4), p.1608-1619
• Main Authors: Adelman, Daphne, Truong Thanh, Xuan-Mai, Feuilly, Marion, Houchard, Aude, Cella, David
• Format: Article
• Language: English
• Subjects: Adult; Antineoplastic Agents, Hormonal - administration & dosage; Antineoplastic Agents, Hormonal - therapeutic use; Attitude of Health Personnel; Cardiology; Delayed-Action Preparations - therapeutic use; Endocrinology; Female; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Neuroendocrine Tumors - diet therapy; Neuroendocrine Tumors - nursing; Octreotide - administration & dosage; Octreotide - therapeutic use; Oncology; Original Research; Peptides, Cyclic - administration & dosage; Peptides, Cyclic - therapeutic use; Pharmacology/Toxicology; Prospective Studies; Rheumatology; Somatostatin - administration & dosage; Somatostatin - analogs & derivatives; Somatostatin - therapeutic use; Surveys and Questionnaires; Syringes
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/s12325-020-01255-8

Introduction Somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours (NETs) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume in patients with acromegaly. A new syringe for lanreotide autogel/depot (LAN) was developed following feedback from a human factors study to improve ease of injection compared with previous syringes. PRESTO aimed to assess preferences of nurses between the LAN new syringe and the octreotide long-acting release (LAR) syringe. Methods PRESTO, a multinational, multicentre, prospective, noninterventional, simulated-use study, enrolled nurses with ≥ 2 years’ experience injecting LAN and/or octreotide LAR in patients with NETs and/or acromegaly. Nurses administered injections into pads using the LAN new syringe and octreotide LAR syringe in a randomised sequence. In an anonymous web-based questionnaire, nurses reported their overall preference (‘strong’ or ‘slight’; primary endpoint) and rated and ranked the importance of nine attributes for each syringe (1 [not at all] to 5 [very much]). Results Overall, 90 nurses attended sessions and completed valid questionnaires. Most nurses (97.8%) expressed a preference (85.6% ‘strong’, 12.2% ‘slight’) for the LAN new syringe versus the octreotide LAR syringe ( P